Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

3.745 -0.035 (-0.93%)

Delayed Quote Updated: 11:05 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Wednesday's session: gap up and gap down stocks ↗

September 03, 2025

Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Nasdaq Gains Over 100 Points; Dollar Tree Post Upbeat Earnings ↗

September 03, 2025

Via Benzinga

Which stocks are moving before the opening bell on Wednesday? ↗

September 03, 2025

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 03, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Insights into WAVE Life Sciences's Upcoming Earnings ↗

July 29, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

September 03, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

August 04, 2025

Via Benzinga

Beyond The Numbers: 6 Analysts Discuss WAVE Life Sciences Stock ↗

August 04, 2025

Via Benzinga

Wave (WVE) Q2 Revenue Drops 56% ↗

July 31, 2025

Via The Motley Fool

WAVE Life Sciences Earnings Preview ↗

May 07, 2025

Via Benzinga

Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q2 2025 Earnings: Revenue Miss but Narrower Loss and Clinical Progress Boost Shares ↗

July 30, 2025

Wave Life Sciences Q2 2025 results show $8.7M revenue miss but narrower EPS loss. Stock rises on optimism for WVE-006's AATD clinical progress.

Via Chartmill

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

July 30, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

July 28, 2025

Via Benzinga

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

July 23, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views ↗

July 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 10, 2025

Via Benzinga

Where WAVE Life Sciences Stands With Analysts ↗

June 23, 2025

Via Benzinga

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 20, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025

Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical development of Wave’s robust RNA medicines pipeline

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 08, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

May 01, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts ↗

April 29, 2025

Via Benzinga

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year ↗

March 26, 2025

Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.

Via Benzinga

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

March 26, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 04, 2025

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Earnings Scheduled For March 4, 2025 ↗

March 04, 2025

Via Benzinga

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

February 25, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.